Syndecan-1 modulates β-integrin-dependent and interleukin-6-dependent functions in breast cancer cell adhesion, migration, and resistance to irradiation

FEBS Journal

Volumn 280, Issue 10, 2013, Pages 2216-2227

  Hassan, Hebatallah ^a,b   Greve, Burkhard ^a   Pavao, Mauro S G ^c   Kiesel, Ludwig ^a   Ibrahim, Sherif A ^a,b   Götte, Martin ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b CAIRO UNIVERSITY   (Egypt)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

focal adhesion kinase; integrin; interleukin 6 (IL 6); irradiation resistance; syndecan

Indexed keywords

BETA INTEGRIN; BETA1 INTEGRIN; FIBRONECTIN; FOCAL ADHESION KINASE; GLYCYLARGINYLGLYCYLASPARTYLSERYLPROLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; REAGENT; SMALL INTERFERING RNA; SYNDECAN 1;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL ADHESION; CELL MIGRATION; CELL STRAIN; CELL STRAIN MDA MB 231; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN FUNCTION; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; STIMULATION; TUMOR MICROENVIRONMENT;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MIGRATION ASSAYS; CELL MOVEMENT; ENZYME ACTIVATION; FEMALE; FIBRONECTINS; FOCAL ADHESION KINASE 1; HUMANS; INTEGRIN ALPHA5BETA1; INTERLEUKIN-6; NF-KAPPA B; OLIGOPEPTIDES; PHOTONS; RADIATION TOLERANCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SYNDECAN-1; TRANSFECTION; TUMOR MICROENVIRONMENT; TUMOR STEM CELL ASSAY;

EID: 84877723436     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12111     Document Type: Article

References (70)

1. Bernfield M, Götte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, &, Zako M, (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68, 729-777. (Pubitemid 29449208)
2. Götte M, (2003) Syndecans in inflammation. FASEB J 17, 575-591. (Pubitemid 37221142)
3. Lambaerts K, Wilcox-Adelman SA, &, Zimmermann P, (2009) The signaling mechanisms of syndecan heparan sulfate proteoglycans. Curr Opin Cell Biol 21, 662-669.
4. Beauvais DM, Ell BJ, McWhorter AR, &, Rapraeger AC, (2009) Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J Exp Med 206, 691-705.
5. Yip GW, Smollich M, &, Götte M, (2006) Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Ther 5, 2139-2148. (Pubitemid 44530449)
6. Afratis N, Gialeli C, Nikitovic D, Tsegenidis T, Karousou E, Theocharis AD, Pavão MS, Tzanakakis GN, &, Karamanos NK, (2012) Glycosaminoglycans: key players in cancer cell biology and treatment. FEBS J 279, 1177-1197.
7. Theocharis AD, Skandalis SS, Tzanakakis GN, &, Karamanos NK, (2010) Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 277, 3904-3923.
8. Nikolova V, Koo CY, Ibrahim SA, Wang Z, Spillmann D, Dreier R, Kelsch R, Fischgräbe J, Smollich M, Rossi LH, et al,. (2009) Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 30, 397-407.
9. Gialeli C, Theocharis AD, &, Karamanos NK, (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278, 16-27.
10. Manon-Jensen T, Itoh Y, &, Couchman JR, (2010) Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J 277, 3876-3889.
11. Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, Veronese S, Caffo O, Lucenti A, Palma PD, et al,. (2003) High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 98, 474-483. (Pubitemid 36885986)
12. Leivonen M, Lundin J, Nordling S, von Boguslawski K, &, Haglund C, (2004) Prognostic value of syndecan-1 expression in breast cancer. Oncology 67, 11-18. (Pubitemid 39370345)
13. Loussouarn D, Campion L, Sagan C, Frenel JS, Dravet F, Classe JM, Pioud-Martigny R, Berton-Rigaud D, Bourbouloux E, Mosnier JF, et al,. (2008) Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. Br J Cancer 98, 1993-1998. (Pubitemid 351821565)
14. Götte M, Kersting C, Ruggiero M, Tio J, Tulusan AH, Kiesel L, &, Wülfing P, (2006) Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer. Anticancer Res 26, 621-627. (Pubitemid 43206026)
15. Tokes AM, Szasz AM, Farkas A, Toth AI, Dank M, Harsanyi L, Molnar BA, Molnar IA, Laszlo Z, Rusz Z, et al,. (2009) Stromal matrix protein expression following preoperative systemic therapy in breast cancer. Clin Cancer Res 15, 731-739.
16. Ibrahim SA, Yip GW, Stock C, Pan JW, Neubauer C, Poeter M, Pupjalis D, Koo CY, Kelsch R, Schüle R, et al,. (2012) Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase- and E-cadherin-dependent mechanism. Int J Cancer 131, E884-E896.
17. Hannafon BN, Sebastiani P, de las Morenas A, Lu J, Rosenberg CL, (2011) Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Res 13, R24, doi: 10.1186/bcr2839.
18. Götte M, Kersting C, Radke I, Kiesel L, &, Wulfing P, (2007) An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res 9, R8, doi: 10.1186/bcr1641.
19. Hanahan D, &, Weinberg R, (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674.
20. Guo Y, Xu F, Lu T, Duan Z, &, Zhang Z, (2012) Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38, 904-910.
21. Speirs V, Kerin MJ, Walton DS, Newton CS, Desai SB, &, Atkin SL, (2000) Direct activation of oestrogen receptor-alpha by interleukin-6 in primary cultures of breast cancer epithelial cells. Br J Cancer 82, 1312-1316. (Pubitemid 30145351)
22. Purohit A, Newman SP, &, Reed MJ, (2002) The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res 4, 65-69. (Pubitemid 34248122)
23. Ramsden L, &, Rider CC, (1992) Selective and differential binding of interleukin (IL)-1 alpha, IL-1 beta, IL-2 and IL-6 to glycosaminoglycans. Eur J Immunol 22, 3027-3031.
24. Mummery RS, &, Rider CC, (2000) Characterization of the heparin-binding properties of IL-6. J Immunol 165, 5671-5679.
25. Sneed TB, Stanley DJ, Young LA, &, Sanderson RD, (1994) Interleukin-6 regulates expression of the syndecan-1 proteoglycan on B lymphoid cells. Cell Immunol 153, 456-467. (Pubitemid 24078621)
26. Sebestyén A, Gallai M, Knittel T, Ambrust T, Ramadori G, &, Kovalszky I, (2000) Cytokine regulation of syndecan expression in cells of liver origin. Cytokine 12, 1557-1560.
27. Kharabi Masouleh B, Ten Dam GB, Wild MK, Seelige R, van der Vlag J, Rops AL, Echtermeyer FG, Vestweber D, van Kuppevelt TH, Kiesel L, et al,. (2009) Role of the heparan sulfate proteoglycan syndecan-1 (CD138) in delayed-type hypersensitivity. J Immunol 182, 4985-4993.
28. Rops AL, Götte M, Baselmans MH, van den Hoven MJ, Steenbergen EJ, Lensen JF, Wijnhoven TJ, Cevikbas F, van den Heuvel LP, van Kuppevelt TH, et al,. (2007) Syndecan-1 deficiency aggravates anti-glomerular basement membrane nephritis. Kidney Int 72, 1204-1215. (Pubitemid 350059661)
29. Schneider C, Kässens N, Greve B, Hassan H, Schüring AN, Starzinski-Powitz A, Kiesel L, Seidler DG, &, Götte M, (2013) Targeting of syndecan-1 by microRNA miR-10b modulates invasiveness of endometriotic cells via dysregulation of the proteolytic millieu and IL-6 secretion. Fertil Steril [Epub ahead of print] doi: 10.1016/j.fertnstert.2012.10.051.
30. Keely PJ, (2011) Mechanisms by which the extracellular matrix and integrin signaling act to regulate the switch between tumor suppression and tumor promotion. J Mammary Gland Biol Neoplasia 16, 205-219.
31. Teng YH, Aquino RS, &, Park PW, (2012) Molecular functions of syndecan-1 in disease. Matrix Biol 31, 3-16.
32. Lahlou H, &, Muller WJ, (2011) β1-integrins signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer. Breast Cancer Res 13, 229-238.
33. Beauvais DM, &, Rapraeger AC, (2003) Syndecan-1-mediated cell spreading requires signaling by alphavbeta3 integrins in human breast carcinoma cells. Exp Cell Res 286, 219-232. (Pubitemid 36566435)
34. Hehlgans S, Eke I, &, Cordes N, (2012) Targeting FAK radiosensitizes 3-dimensional grown human HNSCC cells through reduced Akt1 and MEK1/2 signaling. Int J Radiat Oncol Biol Phys 83, e669-e676.
35. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, &, Frame MC, (2005) The role of focal-adhesion kinase in cancer-a new therapeutic opportunity. Nat Rev Cancer 5, 505-515. (Pubitemid 40942827)
36. Cordes N, Frick S, Brunner TB, Pilarsky C, Grützmann R, Sipos B, Klöppel G, McKenna WG, &, Bernhard EJ, (2007) Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1. Oncogene 26, 6851-6862. (Pubitemid 47609078)
37. Eke I, &, Cordes N, (2011) Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures. Radiother Oncol 99, 279-286.
38. Hong DS, Angelo LS, &, Kurzrock R, (2007) Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 110, 1911-1928. (Pubitemid 350036849)
39. Walter M, Liang S, Ghosh S, Hornsby PJ, &, Li R, (2009) Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene 28, 2745-2755.
40. Pierschbacher MD, Hayman EG, &, Ruoslahti E, (1981) Location of the cell-attachment site in fibronectin with monoclonal antibodies and proteolytic fragments of the molecule. Cell 26, 259-267. (Pubitemid 12244503)
41. Uchio E, Kimura R, Huang YH, Fuchigami A, Kadonosono K, Hayashi A, Ishiko H, Aoki K, &, Ohno S, (2007) Antiadenoviral effect of the alpha 5 beta 1 integrin receptor ligand, GRGDSP peptide, in serotypes that cause acute keratoconjunctivitis. Ophthalmologica 221, 326-330. (Pubitemid 47339656)
42. Hynes RO, (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-687. (Pubitemid 35283958)
43. Wang R, Clark RA, Mosher DF, &, Ren XD, (2005) Fibronectin's central cell-binding domain supports focal adhesion formation and Rho signal transduction. J Biol Chem 280, 28803-28810. (Pubitemid 41105782)
44. Van der Flier A, &, Sonnenberg A, (2001) Function and interactions of integrins. Cell Tissue Res 305, 285-298. (Pubitemid 34212122)
45. Iliopoulos D, Hirsch HA, &, Struhl K, (2009) An epigenetic switch involving NF-kappaB, Lin28, Let-7 microRNA, and IL6 links inflammation to cell transformation. Cell 139, 693-706.
46. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, &, Sledge GW Jr, (1997) Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17, 3629-3639. (Pubitemid 27281838)
47. Storch K, &, Cordes N, (2012) Focal adhesion-chromatin linkage controls tumor cell resistance to radio- and chemotherapy. Chemother Res Pract 2012, 319287, doi: 10.1155/2012/319287.
48. Floer M, Götte M, Wild MK, Heidemann J, Gassar ES, Domschke W, Kiesel L, Luegering A, &, Kucharzik T, (2010) Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice. Am J Pathol 176, 146-157.
49. Ishikawa T, &, Kramer RH, (2010) Sdc1 negatively modulates carcinoma cell motility and invasion. Exp Cell Res 316, 951-965.
50. Mitra SK, Hanson DA, &, Schlaepfer DD, (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6, 56-68. (Pubitemid 40064899)
51. Altemeier WA, Schlesinger SY, Buell CA, Brauer R, Rapraeger AC, Parks WC, &, Chen P, (2012) The transmembrane and extracellular domains of syndecan-1 have distinct functions in regulating lung epithelial migration and adhesion. J Biol Chem 287, 34927-34935.
52. Altemeier WA, Schlesinger SY, Buell CA, Parks WC, &, Chen P, (2012) Syndecan-1 controls cell migration by activating Rap1 to regulate focal adhesion disassembly. J Cell Sci 125, 5188-5195.
53. Eke I, Dickreuter E, &, Cordes N, (2012) Enhanced radiosensitivity of head and neck squamous cell carcinoma cells by β1 integrin inhibition. Radiother Oncol 104, 235-242.
54. Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA, &, Dalton WS, (2009) Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 69, 1009-1015.
55. Selander KS, Li L, Watson L, Merrell M, Dahmen H, Heinrich PC, Müller-Newen G, &, Harris KW, (2004) Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy. Cancer Res 64, 6924-6933. (Pubitemid 39331001)
56. Chiu JJ, Sgagias MK, &, Cowan KH, (1996) Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin Cancer Res 2, 215-221. (Pubitemid 26042195)
57. Klein S, de Fougerolles AR, Blaikie P, Khan L, Pepe A, Green CD, Koteliansky V, &, Giancotti FG, (2002) Alpha 5 beta 1 integrin activates an NF-kappa B-dependent program of gene expression important for angiogenesis and inflammation. Mol Cell Biol 22, 5912-5922. (Pubitemid 34815839)
58. Gordon AH, O'Keefe RJ, Schwarz EM, Rosier RN, &, Puzas JE, (2005) Nuclear factor-kappaB-dependent mechanisms in breast cancer cells regulate tumor burden and osteolysis in bone. Cancer Res 65, 3209-3217. (Pubitemid 40524603)
59. Tawfik Amin A, Shiraishi N, Ninomiya S, Tajima M, Inomata M, &, Kitano S, (2010) Activation of nuclear factor kappa B and induction of migration inhibitory factor in tumors by surgical stress of laparotomy versus carbon dioxide pneumoperitoneum: an animal experiment. Surg Endosc 24, 578-583.
60. Long H, Xie R, Xiang T, Zhao Z, Lin S, Liang Z, Chen Z, &, Zhu B, (2012) Autocrine CCL5 signaling promotes invasion and migration of CD133 + ovarian cancer stem-like cells via NF-kappa B-mediated MMP-9 upregulation. Stem Cells 30, 2309-2319.
61. Shibayama H, Tagawa S, Hattori H, Harigaya K, Taga T, Machii T, &, Kitani T, (1996) Interleukin-6 inhibits the chemotaxis of human malignant plasma cell lines. Br J Haematol 93, 534-541. (Pubitemid 26167363)
62. Lu X, Chen J, Malumbres R, Cubedo Gil E, Helfman DM, &, Lossos IS, (2007) HGAL, a lymphoma prognostic biomarker, interacts with the cytoskeleton and mediates the effects of IL-6 on cell migration. Blood 110, 4268-4277. (Pubitemid 351377791)
63. Kousidou OCh, Berdiaki A, Kletsas D, Zafiropoulos A, Theocharis AD, Tzanakakis GN, &, Karamanos NK, (2008) Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells. Mol Oncol 2, 223-232.
64. Baba F, Swartz K, van Buren R, Eickhoff J, Zhang Y, Wolberg W, &, Friedl A, (2006) Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype. Breast Cancer Res Treat 98, 91-98. (Pubitemid 44050783)
65. Mennerich D, Vogel A, Klaman I, Dahl E, Lichtner RB, Rosenthal A, Pohlenz HD, Thierauch KH, &, Sommer A, (2004) Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumors. Eur J Cancer 40, 1373-1382. (Pubitemid 38737024)
66. Zhang L, Bewick M, &, Lafrenie RM, (2002) Role of Raf-1 and FAK in cell density-dependent regulation of integrin-dependent activation of MAP kinase. Carcinogenesis 23, 1251-1258. (Pubitemid 34814785)
67. Shroff K, &, Kokkoli E, (2012) PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells. Langmuir 28, 4729-4736.
68. Korah R, Boots M, &, Wieder R, (2004) Integrin alpha5beta1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow. Cancer Res 64, 4514-4522. (Pubitemid 38856923)
69. Götte M, Joussen AM, Klein C, Andre P, Wagner DD, Hinkes MT, Kirchhof B, Adamis AP, &, Bernfield M, (2002) Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature. Invest Ophthalmol Vis Sci 43, 1135-1141. (Pubitemid 34258284)
70. Iozzo RV, &, Karamanos N, (2010) Proteoglycans in health and disease: emerging concepts and future directions. FEBS J 277, 3863.